Alumis
Price & Volume
Stats
See more52W Range | $2.76-$13.11 |
Market Cap | $462M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $20M |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $20M |
Diluted EPS | $33.18 |
News
See moreYahoo Finance • last month
Alumis to Participate in Upcoming September Investor Conferences
Yahoo Finance • 2 months ago
TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight
Yahoo Finance • 3 months ago
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Yahoo Finance • 3 months ago
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
About
CEO | Mr. Martin Babler Ph.D. |
Address | 280 East Grand Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 225 |
